Steven Machtinger, MD
Pediatric Allergy/Immunology · San Mateo, CANPI 1093719437
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Genentech USA, Inc. at 34.7% of the total. Reporting peaked in 2020 at $5,012 and has fallen 89.3% since, to $535 in 2025.
Across 71 payments — averaging $169.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$4K
- Boehringer Ingelheim$3K
- Optinose US, Inc.$2K
- Biocryst US Sales Co., LLC$460
- Sanofi$403
- Alk-abello, Inc$276
- plus $2K from 17 others
What the payments were for
- Consulting fees$5,78548%
- Speaking & faculty fees$2,81523%
- Travel & lodging$200%
- Food & beverage$3,33728%
- Education$831%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 5 | $4,178 |
| Boehringer Ingelheim | 5 | $2,904 |
| Optinose US, Inc. | 7 | $2,237 |
| Biocryst US Sales Co., LLC | 5 | $460 |
| Sanofi | 5 | $403 |
| Alk-abello, Inc | 2 | $276 |
| Regeneron Healthcare Solutions, Inc. | 3 | $275 |
| GSK | 9 | $215 |
| Aimmune Therapeutics, Inc. | 2 | $205 |
| Kaleo, Inc. | 4 | $107 |
| Teva Pharmaceuticals USA, Inc. | 1 | $106 |
| Circassia Inc. | 1 | $97 |
| Pfizer | 4 | $95 |
| AstraZeneca | 3 | $71 |
| Amgen | 3 | $61 |
| LEO Pharma Inc. | 2 | $57 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $55 |
| Sanofi-aventis U.S. LLC | 1 | $55 |
| Novartis | 2 | $51 |
| Dermavant Sciences, Inc. | 2 | $48 |
| Lilly USA, LLC | 1 | $31 |
| Insmed, Inc. | 1 | $30 |
| Greer Laboratories, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,040 in reported general payments places this provider in the 70th percentile of 48 pediatric allergy/immunology providers in California.
See all pediatric allergy/immunology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 17 | $120,983 |
| Dupixent SyringeDupilumab | 11 | $42,053 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $21,951 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $17,502 |
| Arnuity ElliptaFluticasone Furoate | 16 | $12,813 |
| Spiriva RespimatTiotropium Bromide | 17 | $12,799 |
| Epinephrine | 30 | $6,261 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $5,887 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $5,836 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $1,816 |
| Ipratropium Bromide | 24 | $667 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $554 |
| Montelukast Sodium | 21 | $174 |
| Prednisone | 14 | $78 |
| Azithromycin | 13 | $74 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $215 | $173,24978 claims |
| Boehringer IngelheimSpiriva Respimat | $2,904 | $12,79917 claims |
| AstraZenecaSymbicort | $71 | $5,88718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 48 pediatric allergy/immunology providers in California.
Other pediatric allergy/immunology in San Mateo
- Manish ButteLos Angeles$357K
- Barbara AriueSan Bernardino$112K
- Peck OngLos Angeles$83K
- Christopher LandonVentura$60K
- Brian GreenbergTarzana$45K
- Alejandro Dorenbaum-KracerPalo Alto$42K
- Maria Garcia-LloretLos Angeles$39K
- Talal ChatilaLos Angeles$30K
- Morna DorseySan Francisco$29K
- Ewald StiehmLos Angeles$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.